Band 5
Provided by Nisha Anand
- Intellectual Property Litigation
- Life Sciences
- Patents
"Canada: SEPs and FRAND – Litigation, Policy and Latest Developments." IAM Media, 8 Dec. 2023, www.iam-media.com/hub/sepfrand-hub/2023/article/canada-seps-and-frand-litigation-policy-and-latest-developments.
“Patented Medicines Notice of Compliance Regulations” Chapter in Blanchard (ed), Life Sciences Law in Canada, 2nd ed (Toronto: Carswell, looseleaf)
Kristin Wall and Nisha Anand: “Recent Trends in Canadian Biologics Patent Litigation” FDLI Update, 2014
Heller, D. & Anand N. “Functional Pharma Claim Flawed, Finds Federal Court of Canada”, APLF IP Law Bugle, 2010
Thornton S, Anand N, Purcell D, Lee J. (2003) Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med. 81(9): 536-48, 2003
Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ, Lee JM. (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet. Jul;31(3):301-5.
Provided by Chambers
Nisha Anand has considerable experience representing clients in patent litigation matters, particularly in the pharmaceutical and energy sectors. She is managing partner at Gilbert's and is based in Toronto.